Share This Page
Drugs in ATC Class P02CB
✉ Email this page to a colleague
Drugs in ATC Class: P02CB - Piperazine and derivatives
| Tradename | Generic Name |
|---|---|
| ANTEPAR | piperazine citrate |
| BRYREL | piperazine citrate |
| HETRAZAN | diethylcarbamazine citrate |
| MULTIFUGE | piperazine citrate |
| PIPERAZINE CITRATE | piperazine citrate |
| VERMIDOL | piperazine citrate |
| >Tradename | >Generic Name |
P02CB Market Analysis and Financial Projection
The ATC class P02CB encompasses piperazine and its derivatives, primarily used as anthelmintics to treat parasitic infections. Diethylcarbamazine, a key drug in this class, is classified under P02CB02 and is widely used for filarial diseases like lymphatic filariasis[1][3][8]. Below is an analysis of the market dynamics and patent landscape for this therapeutic subclass.
Market Dynamics
-
Growth Projections:
The global piperazine derivatives market is projected to exceed USD 3 billion by 2025, growing at a CAGR of 13.1%[4]. This growth is driven by rising demand for anti-parasitic drugs, advancements in synthetic chemistry, and applications in nanomedicine and agrochemicals[4][16]. -
Key Drivers:
- Pharmaceutical Demand: Increased prevalence of parasitic infections (e.g., lymphatic filariasis) and mental health disorders fuels drug development[4][16].
- Diverse Applications: Beyond antiparasitics, derivatives are used in antihistamines, antipsychotics, and fungicides[7][16].
- Emerging Markets: Expanding pharmaceutical sectors in Asia-Pacific and Latin America contribute to growth[4][17].
-
Competitive Landscape:
Major players include Megafine, Rampex Labs, and Vishal Laboratories, which focus on R&D and sustainable manufacturing[4]. The diethylcarbamazine citrate API market is led by companies like Laboratoires Servier and Hikal, targeting antiparasitic drug production[17]. -
Challenges:
- Price Volatility: Off-patent drugs face price hikes due to limited competition[14].
- Regulatory Hurdles: Patent disputes (e.g., Precision BioSciences’ case[10]) and strict quality standards impact market entry[10][17].
Patent Landscape
-
Therapeutic Innovations:
- Neurological Applications: Acyclic piperazine derivatives (US20030191117A1) are patented for treating neuronal damage and stimulating nerve growth[5].
- Antifungals: Bayer’s 2021 patent covers heteroarylpiperidine/piperazine derivatives for agricultural use[7].
- Formulation Patents: Diethylcarbamazine resinate tablets (US4442086A) improve drug stability and efficacy[11].
-
Synthesis Methods:
Recent patents focus on cost-effective piperazine production, such as methods using ethanolamine or hydrogenation processes[13]. These innovations aim to streamline manufacturing for generics[13][14]. -
Litigation and Challenges:
- Patent Disputes: Precision BioSciences successfully defended nine patents related to CAR T-cell therapies, highlighting the value of intellectual property in biotech[10].
- Section 3(d) Barriers: Indian patent law challenges non-innovative derivatives, requiring enhanced efficacy data for approval[7].
-
Trends in R&D:
Over 30% of piperazine-related patents (2010–2015) target CNS disorders, while others explore anticancer, antiviral, and anti-inflammatory applications[16]. Nanomedicine and eco-friendly agrochemicals are emerging foci[4][7].
Key Takeaways
- Market Expansion: Piperazine derivatives are diversifying into non-traditional sectors like targeted drug delivery and sustainable agriculture.
- Strategic Opportunities: Licensing, generics production, and partnerships in emerging markets offer growth avenues[4][15].
- Innovation Barriers: Regulatory scrutiny and patent cliffs necessitate continuous R&D investment to maintain competitiveness[10][14].
FAQs
Q: What is the primary therapeutic use of P02CB-class drugs?
A: Treating parasitic infections (e.g., filariasis) via anthelmintic action[3][8].
Q: Which companies dominate the piperazine derivatives market?
A: Megafine, Rampex Labs, and Basf lead in production and innovation[4][17].
Q: How do patent laws impact the market?
A: Stricter efficacy requirements (e.g., India’s Section 3(d)) and litigation risks shape R&D strategies[7][10].
Q: What future applications are emerging for piperazine derivatives?
A: Nanomedicine, eco-friendly agrochemicals, and neurological therapies[4][5][16].
Q: Why is diethylcarbamazine significant?
A: It remains a frontline treatment for lymphatic filariasis, with API demand driven by global health initiatives[3][17].
References
- https://www.drugsandalcohol.ie/29364/1/WHO%20Collaborating%20Centre%20for%20Drug%20Statistics%20Methodology.pdf
- https://patents.google.com/patent/US3119826A/en
- https://go.drugbank.com/drugs/DB00711
- https://github.com/alekitanis/Market-Research-Report-List-1/blob/main/piperazine-derivatives-market.md
- https://patents.google.com/patent/US20030191117A1/en
- https://carsbits.com/p02cb-turbocharger-supercharger-b-under-boost-condition-causes-symptoms-and-solutions
- https://gipresearch.com/patent-attorney/bayer-intellectual-property-gmbh-granted-patent-for-heteroarylpiperidine-and-piperazine-derivatives-as-fungicides/
- https://en.wikipedia.org/wiki/ATC_code_P02
- https://go.drugbank.com/drugs/DB00592
- https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-us-patent-trial-and-appeal-board
- https://patents.google.com/patent/US4442086A/en
- https://www.youtube.com/watch?v=wee_-9PhJX4
- https://patents.google.com/patent/US6603003B2/en
- https://journals.plos.org/plosntds/article?id=10.1371%2Fjournal.pntd.0007190
- https://pstc.org/wp-content/uploads/2021/05/Rappaport_Matthew.pdf
- https://pubmed.ncbi.nlm.nih.gov/27177234/
- https://www.marketresearchintellect.com/product/global-diethylcarbamazine-citrate-api-market/
More… ↓
